Elevated FGF1 levels are associated with increased angiogenesis and decreased survival in serous ovarian adenocarcinoma [46], and is a potential therapeutic target for ovarian cancer [47, 48]. The gene discussed is FGF1; the disease is ovarian carcinoma.